What's Happening?
At the LSX World Congress in Lisbon, Paulo Neves, Chief Medical Officer of Xeltis, discussed the company's advancements in endogenous tissue restoration for vascular disease. Xeltis is pioneering the development of implants that facilitate the natural
formation of living vessels, aiming to improve care standards for patients undergoing vascular surgeries. Neves highlighted the significant unmet needs in haemodialysis access and coronary arterial bypass surgery, as well as the current investment climate and the importance of global collaboration in advancing medical technologies.
Why It's Important?
Xeltis' work in endogenous tissue restoration represents a significant advancement in medical technology, potentially transforming the treatment landscape for vascular diseases. By enabling the body to naturally create living vessels, these implants could reduce the need for repeated surgeries and improve patient outcomes. This innovation is particularly crucial for patients requiring haemodialysis or coronary bypass surgery, where current solutions often fall short. The discussion at LSX2026 underscores the importance of continued investment and international cooperation in medical research to address these critical healthcare challenges.
